Autus Valve — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Autus Valve is a private, pre-revenue medical device innovator targeting a significant unmet need in pediatric cardiology: durable, growth-accommodating pulmonary valve replacements. The company's core technology is the Autus Valve, a fully synthetic, biomimetic bileaflet valve that is surgically implanted but designed for future transcatheter balloon expansion as the patient grows, eliminating the need for multiple major surgeries. Autus Valve has initiated an FDA-approved pivotal clinical study and is actively enrolling patients, positioning it as a late-stage clinical contender in the congenital heart device market with a highly specialized product.

Cardiovascular

Technology Platform

A fully synthetic, biomimetic bileaflet pulmonary valve designed for surgical implantation and subsequent transcatheter balloon expansion to accommodate patient growth.

Opportunities

The Autus Valve addresses a critical unmet need in pediatric cardiology by potentially eliminating the need for multiple open-heart surgeries as a child grows.

The sizable and chronic patient population with congenital pulmonary valve disease represents a clear market, and a successful product could achieve rapid adoption and premium pricing based on its value proposition of reducing lifetime care costs and improving patient quality of life.

Risk Factors

Key risks include clinical trial failure, regulatory hurdles with the FDA for a novel device design, unproven long-term durability of the synthetic valve through repeated expansions, and challenges in achieving market adoption and reimbursement.

As a single-product, pre-revenue company, it is also highly dependent on securing ongoing financing.

Competitive Landscape

The competitive landscape includes established manufacturers of surgical bioprosthetic and mechanical heart valves (e.g., Edwards Lifesciences, Medtronic, Abbott) and transcatheter pulmonary valves (e.g., Medtronic Harmony, Edwards Alterra). However, Autus Valve's unique value proposition of a surgically implanted, transcatheter-expandable device specifically for pediatric growth is currently novel, giving it a first-mover advantage in a specialized niche if successfully developed.

More companies in United States →